Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

@article{Marks2010GeneDO,
  title={Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial},
  author={William J. Marks and Raymond T. Bartus and Joao Siffert and Charles Stewert Davis and Charles W. Olanow},
  journal={The Lancet Neurology},
  year={2010},
  volume={9},
  pages={1164-1172}
}
BACKGROUND In an open-label phase 1 trial, gene delivery of the trophic factor neurturin via an adeno-associated type-2 vector (AAV2) was well tolerated and seemed to improve motor function in patients with advanced Parkinson's disease. We aimed to assess the safety and efficacy of AAV2-neurturin in a double-blind, phase 2 randomised trial. METHODS We did a multicentre, double-blind, sham-surgery controlled trial in patients with advanced Parkinson's disease. Patients were randomly assigned… CONTINUE READING
BETA